Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

BACKGROUND: Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS: In a phase 3 trial, we r...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:N Engl J Med
मुख्य लेखकों: Shanafelt, Tait D., Wang, Xin V., Kay, Neil E., Hanson, Curtis A., O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong C., Coutre, Steven E., Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6908306/
https://ncbi.nlm.nih.gov/pubmed/31365801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1817073
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन